TRIMETHOPRIM TABLETS

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

TRIMETHOPRIM

可用日期:

AA PHARMA INC

ATC代码:

J01EA01

INN（国际名称）:

TRIMETHOPRIM

剂量:

200MG

药物剂型:

TABLET

组成:

TRIMETHOPRIM 200MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

URINARY ANTI-INFECTIVES

產品總結:

Active ingredient group (AIG) number: 0114346002; AHFS:

授权状态:

APPROVED

授权日期:

2010-06-17

产品特点

PRODUCT MONOGRAPH
TRIMETHOPRIM
TRIMETHOPRIM TABLETS USP
100 MG AND 200 MG
ANTIBACTERIAL AGENT
AA PHARMA INC.
DATE OF REVISION:
1165 CREDITSTONE ROAD, UNIT #1
MAY 14, 2014
VAUGHAN, ON
L4K 4N7
CONTROL #: 172985
- 1 -
PRODUCT MONOGRAPH
TRIMETHOPRIM
Trimethoprim Tablets USP
100 mg and 200 mg
THERAPEUTIC CLASSIFICATION
Antibacterial agent
ACTIONS AND CLINICAL PHARMACOLOGY
Trimethoprim blocks the production of tetrahydrofolic acid from
dihydrofolic acid by binding to
and reversibly inhibiting the enzyme dihydrofolate reductase. This
binding is very much
stronger for the bacterial enzyme than for the corresponding mammalian
enzyme; thus,
trimethoprim selectively interferes with bacterial biosynthesis of
nucleic acids and proteins by
causing a deficiency of endogenously produced thymine. The effect is
usually bactericidal in
the absence of an adequate external supply by thymine or thymidine
(see MICROBIOLOGY).
Trimethoprim is rapidly absorbed following oral administration. It
exists in the blood as
unbound, protein-bound and metabolized forms. Ten to 20% of
trimethoprim is metabolized,
primarily in the liver; the remainder is excreted unchanged in the
urine. The principal
metabolites of trimethoprim are the 1- and 3-oxides and the 3 - and 4
-hydroxy derivatives. The
free form is considered to be the therapeutically active form.
Approximately 44% of
trimethoprim is bound to plasma proteins.
Mean peak serum concentrations of approximately 1.0 µg/mL occur 1 to
4 hours after oral
administration of a single 100 mg dose. A single 200 mg dose will
result in serum levels
approximately twice as high. The half-life of trimethoprim ranges from
8 to 10 hours. However,
patients with severely impaired renal function exhibit an increase in
the half-life of trimethoprim,
which requires either dosage regimen adjustment or not using the drug
in such patients (see
DOSAGE AND ADMINISTRATION). During a 13-week study of trimethoprim
administered at a
daily dosage of 200 mg (50 mg q.i.d.), the mean minimum steady-state
concentration of the
dr